The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of l-kynurenine to kynurenic acid: An in vitro study

Brain Research Bulletin

Volumn 76, Issue 5, 2008, Pages 474-479

  Rozsa, Eva ^a   Robotka, Hermina ^a   Nagy, David ^a   Farkas, Tamas ^a   Sas, Katalin ^a   Vecsei, Laszlo ^a   Toldi, Jozsef ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Epileptic seizure; Hippocampus; In vitro electrophysiology; Kynurenic acid; l Kynurenine; Neuroprotection

Indexed keywords

KYNURENIC ACID; KYNURENINE; N(G) NITROARGININE; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GABA ANTAGONISTS; HIPPOCAMPUS; KYNURENIC ACID; KYNURENINE; NITROARGININE; PENTYLENETETRAZOLE; RATS; RATS, WISTAR;

EID: 44549088278     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2007.12.001     Document Type: Article

References (27)

1. Brito V.B., Folmer V., Puntel G.O., Fachinetto R., Soares J.C., Zeni G., Nogueira C.W., and Rocha J.B. Diphenyl diselenide and 2,3-dimercaptopropanol increase the PTZ-induced chemical seizure and mortality in mice. Brain Res. Bull. 68 (2006) 414-418
2. Dale W.E., Dang Y., Amiridze N., and Brown O.R. Evidence that kynurenine pathway metabolites mediate hyperbaric oxygen-induced convulsions. Toxicol. Lett. 117 (2000) 37-43
3. De Deyn P.P., and Macdonald R.L. Effects of antiepileptic drugs on GABA responses and on reduction of GABA responses by PTZ and DMCM on mouse neurons in cell culture. Epilepsia 30 (1989) 17-25
4. Foster A.C., Vezzani A., French E.D., and Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48 (1984) 273-278
5. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., and Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56 (1991) 2007-2017
6. Fuvesi J., Somlai C., Nemeth H., Varga H., Kis Z., Farkas T., Karoly N., Dobszay M., Penke Z., Penke B., Vecsei L., and Toldi J. Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol. Biochem. Behav. 77 (2004) 95-102
7. Germano I.M., Pitts L.H., Meldrum B.S., Bartkowski H.M., and Simon R.P. Kynurenate inhibition of cell excitation decreases stroke size and deficits. Ann. Neurol. 22 (1987) 730-734
8. Giles G.I., Collins C.A., Stone T.W., and Jacob C. Electrochemical and in vitro evaluation of the redox properties of kynurenine species. Biochem. Biophy. Res. Commun. 300 (2003) 719-724
9. Herrling P.L. Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: evidence for its mediation by quisqualate- or kainate-receptors. Neuroscience 14 (1985) 417-426
10. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., and Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001) 7463-7473
11. Kemp J.A., Foster A.C., Leeson P.D., Priestley T., Tridgett R., Iversen L.L., and Woodruff G.N. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-d-aspartate receptor complex. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6547-6550
12. Kessler M., Terramani T., Lynch G., and Baudry M. A glycine site associated with N-methyl-d-aspartic acid receptors-characterization and identification of a new class of antagonists. J. Neurochem. 52 (1989) 1319-1328
13. Klivenyi P., Toldi J., and Vecsei L. Kynurenines in neurodegenerative disorders: therapeutic considerations. Adv. Exp. Med. Biol. 541 (2004) 169-183
14. Leeson P.D., and Iversen L.L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 37 (1994) 4053-4067
15. Luchowski P., Kocki T., and Urbanska E.M. N(G)-nitro-l-arginine and its methyl ester inhibit brain synthesis of kynurenic acid possibly via nitric oxide-independent mechanism. Polish J. Pharmacol. 53 (2001) 597-604
16. Macdonald R.L., and Barker J.L. Penicillin and pentylenetetrazol selectively antagonize GABA-mediated postsynaptic inhibition of cultured mammalian neurons. Neurology 27 (1977) 337-1337
17. McNamara D., Smith E.C., Calligaro D.O., O'Malley P.J., McQuaid L.A., and Dingledine R. 5,7-Dichlorokynurenic acid, a potent and selective competitive antagonist of the glycine site on NMDA receptors. Neurosci. Lett. 120 (1990) 17-20
18. Nemeth H., Robotka H., Kis Z., Rozsa E., Janaky T., Somlai C., Marosi M., Farkas T., Toldi J., and Vecsei L. Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology 47 (2004) 916-925
19. Nemeth H., Toldi J., and Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr. Neurovasc. Res. 2 (2005) 249-260
20. Nemeth H., Toldi J., Vecsei L., and Kynurenines. Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural Trans. 70 (2006) 1-20
21. Perkins M.N., and Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 (1982) 184-187
22. Scharfman H.E., Hodkins P.S., Lee S., and Schwarcz R. Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices. Neurosci. Lett. 274 (1999) 111-114
23. Schwarcz R., and Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Therap. 303 (2002) 1-10
24. Stone T.W., Mackay G.M., Forrest C.M., Clark C.J., and Darlington L.G. Tryptophan metabolites and brain disorders. Clin. Chem. Lab. Med. 41 (2003) 852-859
25. Tchekalarova J., and Georgiev V. Effect of acute versus chronic theophylline administration on acute restraint stress-induced increase of pentylenetetrazol seizure threshold in mice. Brain Res. Bull. 68 (2006) 464-468
26. Turski W.A., Gramsbergen J.B., Traitler H., and Schwarcz R. Rat brain slices produce and liberate kynurenic acid upon exposure to l-kynurenine. J. Neurochem. 52 (1989) 1629-1636
27. Yudkoff M., Daikhin Y., Nissim I., Horyn O., Luhovyy B., Lazarow A., and Nissim I. Short-term fasting, seizure control and brain amino acid metabolism. Neurochem. Int. 48 (2006) 650-656